Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01216540 · ClinicalTrials.gov registry record
Vancomycin-Associated Nephrotoxicity
A clinical trial, sponsored by University at Buffalo.
- Completed
- Registry status
- 398
- Enrollment target
NCT01216540: Completed study, sponsored by University at Buffalo.
NCT01216540 is a clinical trial that has completed, run by University at Buffalo. The registered enrollment target is 398 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01216540 has completed, sponsored by University at Buffalo.
- COMPLETED
- Registry status
- 398 participants
- Enrollment target
Study Summary
The primary goal of this study is to determine if there is an association between greater exposure to vancomycin and the development of nephrotoxicity. The secondary goal is to estimate the costs to the hospital associated with these nephrotoxic events.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 398 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-04 |
What the finished NCT01216540 record still lists
NCT01216540 is an observational study that tracks outcomes without assigning an intervention. The registered 398 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01216540 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01216540 about?
NCT01216540 is a clinical study titled "Vancomycin-Associated Nephrotoxicity". The primary goal of this study is to determine if there is an association between greater exposure to vancomycin and the development of nephrotoxicity. The secondary goal is to estimate the costs to the hospital associated with these nephrotoxic events.
What is the current status of trial NCT01216540?
This trial is currently completed. The enrollment target is 398 participants. The study started on 2010-11. Estimated completion is 2011-04.
Who is sponsoring clinical trial NCT01216540?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05365581 · 398 participants · Phase 1
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- NCT03165734 · 399 participants · Phase 3
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
- NCT05022862 · 399 participants · NA
Economic Incentives and vDOT for Latent Tuberculosis Infection
- NCT00601939 · 397 participants · NA
Effectiveness of Empowerment Group Sessions for Treating Suicidal African American Women in Abusive Relationships
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia